These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21418051)

  • 1. Insights on the robust variance estimator under recurrent-events model.
    Al-Khalidi HR; Hong Y; Fleming TR; Therneau TM
    Biometrics; 2011 Dec; 67(4):1564-72. PubMed ID: 21418051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of health care utilization in patients receiving implantable cardioverter-defibrillator therapies: An analysis of the managed ventricular pacing trial.
    Rickard J; Whellen D; Sherfesee L; Peterson BJ; Nahey T; Tang AS; Ellenbogen KA; Cheng A
    Heart Rhythm; 2017 Sep; 14(9):1382-1387. PubMed ID: 28385672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
    Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of a randomized clinical trial comparing stress reduction treatment to usual cardiac care: the Reducing Vulnerability to Implantable Cardioverter Defibrillator Shock-Treated Ventricular Arrhythmias (RISTA) trial.
    Donahue RG; Lampert R; Dornelas E; Clemow L; Burg MM;
    Psychosom Med; 2010 Feb; 72(2):172-7. PubMed ID: 20028832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial.
    Dorian P; Al-Khalidi HR; Hohnloser SH; Brum JM; Dunnmon PM; Pratt CM; Holroyde MJ; Kowey P;
    J Am Coll Cardiol; 2008 Sep; 52(13):1076-83. PubMed ID: 18848141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.
    Greenlee RT; Go AS; Peterson PN; Cassidy-Bushrow AE; Gaber C; Garcia-Montilla R; Glenn KA; Gupta N; Gurwitz JH; Hammill SC; Hayes JJ; Kadish A; Magid DJ; McManus DD; Multerer D; Powers JD; Reifler LM; Reynolds K; Schuger C; Sharma PP; Smith DH; Suits M; Sung SH; Varosy PD; Vidaillet HJ; Masoudi FA
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29581222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn.
    Jarman JW; Todd DM
    Europace; 2013 Aug; 15(8):1158-65. PubMed ID: 23449924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.
    Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I
    JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.
    Barsheshet A; Goldenberg I; Moss AJ; Huang DT; Zareba W; McNitt S; Klein HU; Guetta V
    J Cardiovasc Electrophysiol; 2011 Nov; 22(11):1237-42. PubMed ID: 21615813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis.
    Briongos-Figuero S; Estévez A; Luisa Pérez M; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Basterra N; Rodríguez A; Lozano I; Muñoz-Aguilera R
    Int J Cardiol; 2019 Jan; 274():163-169. PubMed ID: 30206014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.
    Gasparini M; Proclemer A; Klersy C; Kloppe A; Lunati M; Ferrer JB; Hersi A; Gulaj M; Wijfels MC; Santi E; Manotta L; Arenal A
    JAMA; 2013 May; 309(18):1903-11. PubMed ID: 23652522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions.
    Gojkovic O; Aliot EM; Capucci A; Connolly SJ; Crijns H; Hohnloser SH; Kulakowski P; Roy D; Radzik D; Singh BN; Kowey PR
    Heart Rhythm; 2012 Feb; 9(2):217-224.e2. PubMed ID: 21978965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
    Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
    Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival after implantable cardioverter-defibrillator implantation in the elderly.
    Yung D; Birnie D; Dorian P; Healey JS; Simpson CS; Crystal E; Krahn AD; Khaykin Y; Cameron D; Chen Z; Lee DS
    Circulation; 2013 Jun; 127(24):2383-92. PubMed ID: 23775193
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.